BioSpace News Archive

Spectrum Pharmaceuticals Presents Same Day Dosing Data for ROLONTIS ® (eflapegrastim) at AACR Virtual Annual Meeting II

ImmunSYS, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products, reported results from a proof of concept (PoC) study evaluating its proprietary technology platform, YourVaccx for the treatment of patients with metastatic cancers.

NANO-X IMAGING LTD (www.nanox.vision) (“Nanox” or the “Company”), an innovative medical imaging technology company, announces it has signed an exclusive distribution agreement with Golden Vine International (廖佩玲) (“Golden Vine”), for the introduction of affordable advanced medical imaging services in Taiwan and Singapore.

Gene editing of engineered natural killer cells contributed to enhanced cell persistence and tumor killing Combination of engineered natural killer cells and engineered T cells demonstrated potential to achieve improved tumor control, optimized cell proliferation and moderate levels of cytokine accumulation SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nkarta), a privately-held biopharmaceutical company developing engineered natural killer (NK) cell thera

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that management will present at SVB Leerink’s CybeRx Series: 2 nd Annual CNS Forum. Additional details can be found below: Title: A Pipeline Update with Scott Braunstein (CEO) and Joe Hulihan (CMO) Date: Tuesday, June 23, 2020 Time: 3:20 PM Easter

Roflumilast foam potential “Best in Class” topical PDE4 inhibitor in foam formulation Seborrheic dermatitis affects over 6 million U.S. patients Phase 2 topline data anticipated early in fourth quarter of 2020 The Company also announced first patient enrolled in long-term safety study WESTLAKE VILLAGE, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for un

Next Generation ALK Inhibitor Candidate, TPX-0131, Overcomes ALK Resistant Mutations in Preclinical Models

SOTIO and Cytune Pharma from the PPF Group, today presented new preclinical data highlighting the therapeutic potential of SO-C101, an IL-15 superagonist, as a monotherapy and in combination with PD-1 inhibitors in multiple tumor models. The data were presented in a virtual poster presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II. “SO-C101 is a highly promising modality in immuno-oncology giv

--World-Class Monoclonal Antibody Technology Advances Beyond Infectious Disease to Focus on Oncology Therapeutics Derived from Cancer Survivors-- --Lead Asset AT1412 On Track Towards CTA Filing in Q4 2020-- --Led by New Management Team, Including John Womelsdorf, Ph.D., and Hans van Eenennaam, Ph.D., Co-inventor of Pembrolizumab-- l

As many Canadians are limiting their grocery trips and using up the food they have at home during the COVID-19 pandemic, Health Canada is providing them with important information on best-before and expiration dates of foods.